20 studies found for:    Lupus AND Los Angeles | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Abatacept for SLE Arthritis (IM101-330)
Condition: Systemic Lupus Erythematosus Arthritis
Interventions: Drug: abatacept;   Drug: Placebo
2 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
3 Recruiting A Complex Contraception Registry
Conditions: Diabetes;   Cardiovascular Disease;   Epilepsy;   Migraine;   Neurological Disorders;   Cancer;   Bariatric Surgery Candidate;   Organ or Tissue Transplant; Complications;   Lupus Erythematosus, Systemic;   Other Hematologic Conditions;   Other Venous Embolism and Thrombosis
Intervention:
4 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
5 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir
6 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
7 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
8 Recruiting A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Baricitinib;   Drug: Placebo
9 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
10 Recruiting Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Anifrolumab;   Drug: Placebo
11 Recruiting A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: IPP-201101;   Drug: Placebo;   Other: Standard of Care
12 Recruiting Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
13 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
14 Recruiting Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: BI 655064 dose 1;   Drug: BI 655064 dose 2;   Drug: BI 655064 dose 3;   Drug: Placebo
15 Recruiting A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an Antibody Targeting Certain Types of Immune Cells, in Participants With Lupus Nephritis (LN)
Condition: Lupus Nephritis
Interventions: Drug: Mycophenolate Mofetil;   Drug: Obinutuzumab;   Drug: Placebo
16 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
17 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
18 Not yet recruiting MsciSLE: MSCs in SLE Trial
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Low Dose Mesenchymal Stem Cells (MSCs);   Drug: High Dose Mesenchymal Stem Cells (MSCs);   Drug: Placebo Infusion
19 Recruiting Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept
20 Recruiting Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)
Condition: All Diagnosed Health Conditions
Intervention:

Indicates status has not been verified in more than two years